CPMD (Cannapharmarx) 1-Year ROIIC % : -230.61% (As of Mar. 2026)


What is Cannapharmarx 1-Year ROIIC %?

Cannapharmarx CPMD +15.00% 1-Year ROIIC % is -230.61 as of Mar. 2026. The stock has 6 warning signs investors should review. Among 967 Drug Manufacturers companies, Cannapharmarx ranks worse than 93.49% on this metric.

1-Year Return on Invested Incremental Capital (1-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 1-year. Cannapharmarx's 1-Year ROIIC % for the quarter that ended in Mar. 2026 was -230.61%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.

The industry rank for Cannapharmarx's 1-Year ROIIC % or its related term are showing as below:

CPMD's 1-Year ROIIC % is ranked worse than
93.49% of 967 companies
in the Drug Manufacturers industry
Industry Median: 1.3 vs CPMD: -230.61

Cannapharmarx  (OTCPK:CPMD) 1-Year ROIIC % Explanation

Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.

High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.

Be Aware

It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.


Cannapharmarx 1-Year ROIIC % Related Terms


Cannapharmarx 1-Year ROIIC % Historical Data

* Premium members only.

The historical data trend for Cannapharmarx's 1-Year ROIIC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cannapharmarx 1-Year ROIIC % Chart

Cannapharmarx Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
1-Year ROIIC %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -16.34 -37.95 108.40 -44.00 0.21

Cannapharmarx Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
1-Year ROIIC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 26.34 -97.56 -61.83 0.21 -230.61

CPMD vs NPHC, BSPK, UPC: 1-Year ROIIC % Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Cannapharmarx's 1-Year ROIIC %, along with its competitors' market caps and 1-Year ROIIC % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cannapharmarx 1-Year ROIIC % vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Cannapharmarx's 1-Year ROIIC % distribution charts can be found below:

* The bar in red indicates where Cannapharmarx's 1-Year ROIIC % falls into.



Cannapharmarx 1-Year ROIIC % Calculation

Cannapharmarx's 1-Year ROIIC % for the quarter that ended in Mar. 2026 is calculated as:

1-Year ROIIC %=1-Year Incremental Net Operating Profit After Taxes (NOPAT)**/1-Year Incremental Invested Capital
=( -3.353 (Mar. 2026) - -3.24 (Mar. 2025) )/( 24.318 (Mar. 2026) - 24.269 (Mar. 2025) )
=-0.113/0.049000000000003
=-230.61%***

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** TTM data of NOPAT and Invested Capital was used to calculate 1-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.

Frequently Asked Questions Learn more about 1-Year ROIIC % →
What does a 1-Year ROIIC % of -230.61 mean?
Cannapharmarx (CPMD) has a 1-Year ROIIC % of -230.61 as of Mar. 2026. 1-Year ROIIC % measures the change in earnings as a percentage of change in investment over 1-year. View historical data on Cannapharmarx and its competitors. According to the industry distribution chart, Cannapharmarx ranks #904 out of 967 companies in the Drug Manufacturers industry, placing it in the top 93.5%.
Is Cannapharmarx's 1-Year ROIIC % too high?
Cannapharmarx's current 1-Year ROIIC % is -230.61. Based on the distribution chart, Cannapharmarx ranks #904 out of 967 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers.
How does Cannapharmarx's 1-Year ROIIC % compare to NPHC and BSPK?
According to the Drug Manufacturers industry distribution chart, Cannapharmarx ranks #904 out of 967 companies for 1-Year ROIIC %. This places Cannapharmarx in the lower half of its industry. The industry median 1-Year ROIIC % is 1.30. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 1-Year ROIIC % for a Drug Manufacturers company?
The median 1-Year ROIIC % among Drug Manufacturers companies is 1.30, based on 967 companies in the industry. Companies in the top quartile (top 25%) have a 1-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 1-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 1-Year ROIIC % mean?
A high 1-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 1-Year ROIIC % measures the change in earnings as a percentage of change in investment over 1-year. View historical data on Cannapharmarx and its competitors. For the Drug Manufacturers industry, the median 1-Year ROIIC % is 1.30 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cannapharmarx's current 1-Year ROIIC % is -230.61. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cannapharmarx stock overvalued right now?
Cannapharmarx (CPMD) has a current 1-Year ROIIC % of -230.61. The current 1-Year ROIIC % is -230.61. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 1-Year ROIIC % calculated?
1-Year ROIIC % is calculated from a company's financial statements. For Cannapharmarx (CPMD), the current 1-Year ROIIC % is -230.61 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Cannapharmarx Business Description

Address 4439 Township Road 304, Suite 302, Mountain View County, Central Alberta, AB, CAN, T0M 0R0
Cannapharmarx Inc specializes in the acquisition, development, and operation of cannabis cultivation facilities in Canada. The group evolved to focus on producing medical cannabis and craft products. The products of the company are Unique Genetics, Craft Products, and Medical Cannabis.